From Pulse 2.0 · Amit Chowdhry · · 30s
TL;DR: Arcturus Meiji Investment Details
Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech.
Arcturus Therapeutics received $50 million from Meiji Seika Pharma at 80% premium for its mRNA platform, accelerating cystic fibrosis and ornithine transcarbamylase deficiency treatments. Arcturus Therapeutics secures $50m Meiji investment at 80% premium for mRNA tech. Meiji purchases Arcturus securities at $20.27 per share, an 80% premium, representing 7.9% of shares. Arcturus licenses ARCT-154 technology for an undisclosed therapeutic area.
- Investment Terms
- Technology License
- Pandemic Partnership
Read the story version — the same reporting as a swipeable deck of 3 cards.

